CVOT data for Novo’s Wegovy set bar for health benefit in obesity

New cardiovascular outcomes data for Novo’s Wegovy likely sets a bar that other mechanisms for treating obesity will have to meet or clear to compete with the GLP-1 class.

The 20% reduction in the risk of major adverse cardiovascular events seen in the Phase III SELECT trial exceeded expectations of Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO), lifting its shares by 17% and creating value among biopharmas developing other therapies in Wegovy semaglutide’s class. ...